|
1
|
Montgomery RL, Hullinger TG, Semus HM,
Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN and
van Rooij E: Therapeutic inhibition of miR-208a improves cardiac
function and survival during heart failure. Circulation.
124:1537–1547. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mozaffarian D, Benjamin EJ, Go AS, Arnett
DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ,
Howard VJ, et al: Heart disease and stroke statistics-2015 update:
A report from the American heart association. Circulation.
131:e29–e322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guha K and McDonagh T: Heart failure
epidemiology: European perspective. Curr Cardiol Rev. 9:123–127.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu SS, Kong LZ, Gao RL, Zhu ML, Wang W,
Wang YJ, Wu ZS, Chen WW and Liu MB; Editorial Board, : Outline of
the report on cardiovascular disease in China, 2010. Biomed Environ
Sci. 25:251–256. 2012.PubMed/NCBI
|
|
5
|
Bui AL, Horwich TB and Fonarow GC:
Epidemiology and risk profile of heart failure. Nat Rev Cardiol.
8:30–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Spinelli L, Stabile E, Giugliano G,
Morisco C, Giudice CA, Imbriaco M, Santoro M, Esposito G and
Trimarco B: Intramyocardial dissecting hematoma in anterior wall ST
elevation myocardial infarction: Impact on left ventricular
remodeling and prognosis. Int J Cardiovasc Imaging. Aug
1–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sharma UC, Pokharel S, van Brakel TJ, van
Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ,
Maessen J and Pinto YM: Galectin-3 marks activated macrophages in
failure-prone hypertrophied hearts and contributes to cardiac
dysfunction. Circulation. 110:3121–3128. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu YH, D'Ambrosio M, Liao TD, Peng H,
Rhaleb NE, Sharma U, André S, Gabius HJ and Carretero OA:
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling
and dysfunction induced by galectin-3, a mammalian
adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol.
296:H404–H412. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Boer RA, Yu L and van Veldhuisen DJ:
Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail
Rep. 7:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Henderson NC, Mackinnon AC, Farnworth SL,
Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ and Sethi T:
Galectin-3 regulates myofibroblast activation and hepatic fibrosis.
Proc Natl Acad Sci USA. 103:pp. 5060–5065. 2006; View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Henderson NC, Mackinnon AC, Farnworth SL,
Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J and Sethi T:
Galectin-3 expression and secretion links macrophages to the
promotion of renal fibrosis. Am J Pathol. 172:288–298. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Van den Borne SW, Diez J, Blankesteijn WM,
Verjans J, Hofstra L and Narula J: Myocardial remodeling after
infarction: The role of myofibroblasts. Nat Rev Cardiol. 7:30–37.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Boer RA, Voors AA, Muntendam P, van
Gilst WH and van Veldhuisen DJ: Galectin-3: A novel mediator of
heart failure development and progression. Eur J Heart Fail.
11:811–817. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Anand IS, Rector TS, Kuskowski M, Adourian
A, Muntendam P and Cohn JN: Baseline and serial measurements of
galectin-3 in patients with heart failure: Relationship to
prognosis and effect of treatment with valsartan in the Val-HeFT.
Eur J Heart Fail. 15:511–518. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei F, Wang TZ, Zhang J, Yuan ZY, Tian HY,
Ni YJ, Zhuo XZ, Han K, Liu Y, Lu Q, et al: Mesenchymal stem cells
neither fully acquire the electrophysiological properties of mature
cardiomyocytes nor promote ventricular arrhythmias in infarcted
rats. Basic Res Cardiol. 107:2742012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rodenbaugh DW, Wang W, Davis J, Edwards T,
Potter JD and Metzger JM: Parvalbumin isoforms differentially
accelerate cardiac myocyte relaxation kinetics in an animal model
of diastolic dysfunction. Am J Physiol Heart Circ Physiol.
293:H1705–H1713. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
National Institutes of Health, . Guide for
the Care and Use of Laboratory AnimalsNIH publication no. 85_/23.
National Institutes of Health; Rockville, MD: 1996
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang XH, Zhuo XZ, Ni YJ, Gong M, Wang TZ,
Lu Q and Ma AQ: Improvement of cardiac function and reversal of gap
junction remodeling by neuregulin-1β in volume-overloaded rats with
heart failure. J Geriatr Cardiol. 9:172–179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Niwa M, Miwa Y, Kuzuya T, Iwasaki K,
Haneda M, Ueki T, Katayama A, Hiramitsu T, Goto N, Nagasaka T, et
al: Stimulation index for PCNA mRNA in peripheral blood as immune
function monitoring after renal transplantation. Transplantation.
87:1411–1414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hetz C: BCL-2 protein family. Essential
regulators of cell death. Preface. Adv Exp Med Biol. 687:vii–viii.
2010.PubMed/NCBI
|
|
22
|
Hrynchyshyn N, Jourdain P, Desnos M,
Diebold B and Funck F: Galectin-3: A new biomarker for the
diagnosis, analysis and prognosis of acute and chronic heart
failure. Arch Cardiovasc Dis. 106:541–546. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gaggin HK and Januzzi JL Jr: Biomarkers
and diagnostics in heart failure. Biochim Biophys Acta.
1832:2442–2450. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ho JE, Liu C, Lyass A, Courchesne P,
Pencina MJ, Vasan RS, Larson MG and Levy D: Galectin-3, a marker of
cardiac fibrosis, predicts incident heart failure in the community.
J Am Coll Cardiol. 60:1249–1256. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshii T, Fukumori T, Honjo Y, Inohara H,
Kim HR and Raz A: Galectin-3 phosphorylation is required for its
anti-apoptotic function and cell cycle arrest. J Biol Chem.
277:6852–6857. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin HM, Pestell RG, Raz A and Kim HR:
Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a
cAMP-responsive element in human breast epithelial cells. Oncogene.
21:8001–8010. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu L, Ruifrok WP, Meissner M, Bos EM, van
Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IJ, Koerts
JA, et al: Genetic and pharmacological inhibition of galectin-3
prevents cardiac remodeling by interfering with myocardial
fibrogenesis. Circ Heart Fail. 6:107–117. 2013. View Article : Google Scholar : PubMed/NCBI
|
